SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001104659-11-062842
Filing Date
2011-11-10
Accepted
2011-11-09 21:01:28
Documents
1
Group Members
DANIEL K. TURNER, IIIHOWARD D. PALEFSKYJOHN SAVARESE, M.D.MONTREUX EQUITY MANAGEMENT II SBIC, LLCMONTREUX EQUITY MANAGEMENT III SBIC, LLCMONTREUX EQUITY MANAGEMENT IV, LLCMONTREUX EQUITY PARTNERS III SBIC, L.P.MONTREUX IV ASSOCIATES, L.L.C.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A a11-29579_1sc13da.htm SC 13D/A 347823
  Complete submission text file 0001104659-11-062842.txt   349685
Mailing Address 1003 W. CUTTING BLVD SUITE 110 POINT RICHMOND CA 94804
Business Address 1003 W. CUTTING BLVD SUITE 110 POINT RICHMOND CA 94804 (510) 215-3500
Transcept Pharmaceuticals Inc (Subject) CIK: 0001178711 (see all company filings)

IRS No.: 330960223 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-81821 | Film No.: 111193018
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2500 SAND HILL ROAD SUITE 215 MENLO PARK CA 94025
Business Address
MONTREUX EQUITY PARTNERS II SBIC LP (Filed by) CIK: 0001277894 (see all company filings)

IRS No.: 770530710 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SC 13D/A